After seeing several healthy girls developing a severe chronic illness soon after HPV vaccination , I analyzed all HPV vaccine randomized controlled trials.
The overwhelming majority of pre-licensure HPV vaccine randomized trials did not use inert placebo as comparator. The largest nine-valent HPV immunization trial  compared the newly developed nine-valent HPV vaccine vs. the four-valent HPV formulation. The innovative nine-valent HPV dose has more than double HPV virus-like particles and aluminum adjuvant than the previous formulation. Double-blind safety analysis contrasted 7071 subjects immunized with the nine-valent vaccine vs. 7078 who had the four-valent dose. The nine-valent cohort had significantly more systemic serious adverse events; n = 233 (3.3%) vs. n = 183 (2.6%) in the other group. Our calculated 2 × 2 contingency table p value was 0.0125. Oddly, only two subjects (0%) in each group were judged to have a vaccine-related serious adverse event. The authors did not comment on this incongruity.
This discrepancy arising from a pivotal large randomized double-blind trial suggests that nine-valent HPV vaccine-related serious adverse events were under-recognized. This emerging information casts further doubt on HPV vaccine safety.
Martínez-Lavín M, Martínez-Martínez LA, Reyes-Loyola P (2015) HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol 34:1981–1983
Joura EA, Giuliano AR, Iversen OE et al (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:711–723
About this article
Cite this article
Martínez-Lavín, M. Vaccine-related serious adverse events might have been under-recognized in the pivotal HPV vaccine randomized trial.
Clin Rheumatol 36, 975 (2017). https://doi.org/10.1007/s10067-017-3575-z
- Chronic Illness
- Contingency Table
- Overwhelming Majority
- Safety Analysis
- Vaccine Safety